Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies
The immunomodulatory agent, lenalidomide, is a structural analogue of thalidomide approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome (MDS) and multiple myeloma (MM). This agent is also currently under active investigation for the treatment of chronic lympho...
Saved in:
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2012-01-01
|
| Series: | Advances in Hematology |
| Online Access: | http://dx.doi.org/10.1155/2012/513702 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849407042509340672 |
|---|---|
| author | Jessica M. McDaniel Javier Pinilla-Ibarz P. K. Epling-Burnette |
| author_facet | Jessica M. McDaniel Javier Pinilla-Ibarz P. K. Epling-Burnette |
| author_sort | Jessica M. McDaniel |
| collection | DOAJ |
| description | The immunomodulatory agent, lenalidomide, is a structural analogue of thalidomide approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome (MDS) and multiple myeloma (MM). This agent is also currently under active investigation for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL), as well as in drug combinations for some solid tumors and mantle cell lymphoma (MCL). Although treatment with lenalidomide has translated into a significant extension in overall survival in MM and MDS and has superior safety and efficacy relative to thalidomide, the mechanism of action as it relates to immune modulation remains elusive. Based on preclinical models and clinical trials, lenalidomide, as well as other structural thalidomide derivatives, enhances the proliferative and functional capacity of T-lymphocytes and amplifies costimulatory signaling pathways that activate effector responses and suppress inflammation. This paper summarizes our current understanding of T- and natural killer (NK) cell pathways that are modified by lenalidomide in hematopoietic neoplasms to inform future decisions about potential combination therapies. |
| format | Article |
| id | doaj-art-4655d2c8dc3541a79d54b937e1c867d6 |
| institution | Kabale University |
| issn | 1687-9104 1687-9112 |
| language | English |
| publishDate | 2012-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | Advances in Hematology |
| spelling | doaj-art-4655d2c8dc3541a79d54b937e1c867d62025-08-20T03:36:12ZengWileyAdvances in Hematology1687-91041687-91122012-01-01201210.1155/2012/513702513702Molecular Action of Lenalidomide in Lymphocytes and Hematologic MalignanciesJessica M. McDaniel0Javier Pinilla-Ibarz1P. K. Epling-Burnette2Cancer Biology PhD Program, University of South Florida, Tampa, FL 33620, USADepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USADepartment of Immunology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL 33612, USAThe immunomodulatory agent, lenalidomide, is a structural analogue of thalidomide approved by the US Food and Drug Administration for the treatment of myelodysplastic syndrome (MDS) and multiple myeloma (MM). This agent is also currently under active investigation for the treatment of chronic lymphocytic leukemia (CLL) and non-Hodgkin’s lymphoma (NHL), as well as in drug combinations for some solid tumors and mantle cell lymphoma (MCL). Although treatment with lenalidomide has translated into a significant extension in overall survival in MM and MDS and has superior safety and efficacy relative to thalidomide, the mechanism of action as it relates to immune modulation remains elusive. Based on preclinical models and clinical trials, lenalidomide, as well as other structural thalidomide derivatives, enhances the proliferative and functional capacity of T-lymphocytes and amplifies costimulatory signaling pathways that activate effector responses and suppress inflammation. This paper summarizes our current understanding of T- and natural killer (NK) cell pathways that are modified by lenalidomide in hematopoietic neoplasms to inform future decisions about potential combination therapies.http://dx.doi.org/10.1155/2012/513702 |
| spellingShingle | Jessica M. McDaniel Javier Pinilla-Ibarz P. K. Epling-Burnette Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies Advances in Hematology |
| title | Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies |
| title_full | Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies |
| title_fullStr | Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies |
| title_full_unstemmed | Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies |
| title_short | Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies |
| title_sort | molecular action of lenalidomide in lymphocytes and hematologic malignancies |
| url | http://dx.doi.org/10.1155/2012/513702 |
| work_keys_str_mv | AT jessicammcdaniel molecularactionoflenalidomideinlymphocytesandhematologicmalignancies AT javierpinillaibarz molecularactionoflenalidomideinlymphocytesandhematologicmalignancies AT pkeplingburnette molecularactionoflenalidomideinlymphocytesandhematologicmalignancies |